Ionis Pharmaceuticals, Inc. (IONS)

NMS – Real Time Price. Currency in USD

75.83

+0.45 (0.60%)

At close: May 12, 2026, 4:00 PM EDT

76.00

+0.17 (0.22%)

Pre-market: May 13, 2026, 4:10 AM EDT

04.05.2026

Ionis to host 2026 virtual Annual Meeting of Stockholders

CARLSBAD, Calif.--(BUSINESS WIRE)--Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced that management will conduct its 2026 virtual Annual Meeting of Stockholders followed by a general corporate update on Thursday, June 4, 2026. The agenda for the event is as follows: 5:00 p.m. – 5:15 p.m. ET (2:00 p.m. – 2:15 p.m. PT) – Virtual Annual Meeting of Stockholders All stockholders of record at the close of business on April 7, 2026, are invited to participate in the virtual Annual Meeting we.

30.04.2026

IONS Q1 Earnings & Sales Beat, Stock Rises on Raised '26 View

Ionis tops Q1 estimates and lifts 2026 outlook, drives shares higher as strong drug sales and milestone revenues fuel growth.

29.04.2026

Ionis Pharmaceuticals, Inc. (IONS) Q1 2026 Earnings Call Transcript

29.04.2026

Compared to Estimates, Ionis Pharmaceuticals (IONS) Q1 Earnings: A Look at Key Metrics

While the top- and bottom-line numbers for Ionis Pharmaceuticals (IONS) give a sense of how the business performed in the quarter ended March 2026, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

29.04.2026

Ionis Pharmaceuticals (IONS) Reports Q1 Loss, Tops Revenue Estimates

Ionis Pharmaceuticals (IONS) came out with a quarterly loss of $0.3 per share versus the Zacks Consensus Estimate of a loss of $0.85. This compares to a loss of $0.75 per share a year ago.

29.04.2026

Ionis reports first quarter 2026 financial results and highlights progress on key programs

CARLSBAD, Calif.--(BUSINESS WIRE)--Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) (the “Company”) today reported financial results and provided key updates for the first quarter ended March 31, 2026. “Ionis' strong performance in the first quarter of 2026 underscores the strength of our commercial and R&D engines. Our independent launches are increasingly contributing to revenue, driven by strong commercial execution, and we are on track for two additional groundbreaking independent launches in.

28.04.2026

Ionis partner GSK announces bepirovirsen accepted for Priority Review and granted Breakthrough Therapy Designation by U.S. FDA as a potential first-in-class medicine for chronic hepatitis B

CARLSBAD, Calif.--(BUSINESS WIRE)--Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) partner GSK today announced the U.S. Food and Drug Administration (FDA) has accepted for Priority Review the New Drug Application (NDA) for bepirovirsen, an investigational antisense oligonucleotide (ASO) for the treatment of adults with chronic hepatitis B (CHB). The FDA has granted bepirovirsen Breakthrough Therapy designation and set a Prescription Drug User Fee Act (PDUFA) target action date of October 26, 2026. “.

Ionis reports first quarter 2026 financial results and highlights progress on key programs

28.04.2026

Ionis partner GSK announces bepirovirsen accepted for Priority Review and granted Breakthrough Therapy Designation by U.S. FDA as a potential first-in-class medicine for chronic hepatitis B

21.04.2026

Ionis presents new data from pivotal study of zilganersen in Alexander disease (AxD) at AAN 2026 Annual Meeting

CARLSBAD, Calif.--(BUSINESS WIRE)--Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced additional positive results from the pivotal study of zilganersen in children and adults living with Alexander disease (AxD), a rare, progressive and often fatal neurological condition with no approved disease-modifying treatments. These findings, which will be presented today at the 2026 American Academy of Neurology (AAN) annual meeting, build on previously reported positive topline data and provide.

Ionis Pharmaceuticals, Inc. (IONS)

Get all premium features to the best stock analysis tool

Finranks

Company

Contact us

Follow us

Ionis Pharmaceuticals, Inc. (IONS)

Ionis to host 2026 virtual Annual Meeting of Stockholders

IONS Q1 Earnings & Sales Beat, Stock Rises on Raised '26 View

Ionis Pharmaceuticals, Inc. (IONS) Q1 2026 Earnings Call Transcript

Compared to Estimates, Ionis Pharmaceuticals (IONS) Q1 Earnings: A Look at Key Metrics

Ionis Pharmaceuticals (IONS) Reports Q1 Loss, Tops Revenue Estimates

Ionis reports first quarter 2026 financial results and highlights progress on key programs

Ionis partner GSK announces bepirovirsen accepted for Priority Review and granted Breakthrough Therapy Designation by U.S. FDA as a potential first-in-class medicine for chronic hepatitis B

Videos

Press releases

Ionis to host 2026 virtual Annual Meeting of Stockholders

Ionis reports first quarter 2026 financial results and highlights progress on key programs

Ionis partner GSK announces bepirovirsen accepted for Priority Review and granted Breakthrough Therapy Designation by U.S. FDA as a potential first-in-class medicine for chronic hepatitis B

Ionis presents new data from pivotal study of zilganersen in Alexander disease (AxD) at AAN 2026 Annual Meeting

Ionis to host 2026 virtual Annual Meeting of Stockholders

IONS Q1 Earnings & Sales Beat, Stock Rises on Raised '26 View

Ionis Pharmaceuticals, Inc. (IONS) Q1 2026 Earnings Call Transcript

Compared to Estimates, Ionis Pharmaceuticals (IONS) Q1 Earnings: A Look at Key Metrics

Ionis Pharmaceuticals (IONS) Reports Q1 Loss, Tops Revenue Estimates

Ionis reports first quarter 2026 financial results and highlights progress on key programs

Ionis partner GSK announces bepirovirsen accepted for Priority Review and granted Breakthrough Therapy Designation by U.S. FDA as a potential first-in-class medicine for chronic hepatitis B

Videos

Press releases

Ionis to host 2026 virtual Annual Meeting of Stockholders

Ionis reports first quarter 2026 financial results and highlights progress on key programs

Ionis partner GSK announces bepirovirsen accepted for Priority Review and granted Breakthrough Therapy Designation by U.S. FDA as a potential first-in-class medicine for chronic hepatitis B

Ionis presents new data from pivotal study of zilganersen in Alexander disease (AxD) at AAN 2026 Annual Meeting

Search stocks

Ionis Pharmaceuticals, Inc. (IONS)

Get all premium features to the best stock analysis tool

Finranks

Company

Contact us

Follow us

Ionis Pharmaceuticals, Inc. (IONS)

Ionis to host 2026 virtual Annual Meeting of Stockholders

IONS Q1 Earnings & Sales Beat, Stock Rises on Raised '26 View

Ionis Pharmaceuticals, Inc. (IONS) Q1 2026 Earnings Call Transcript

Compared to Estimates, Ionis Pharmaceuticals (IONS) Q1 Earnings: A Look at Key Metrics

Ionis Pharmaceuticals (IONS) Reports Q1 Loss, Tops Revenue Estimates

Ionis reports first quarter 2026 financial results and highlights progress on key programs

Ionis partner GSK announces bepirovirsen accepted for Priority Review and granted Breakthrough Therapy Designation by U.S. FDA as a potential first-in-class medicine for chronic hepatitis B

Videos

Press releases

Ionis to host 2026 virtual Annual Meeting of Stockholders

Ionis reports first quarter 2026 financial results and highlights progress on key programs

Ionis partner GSK announces bepirovirsen accepted for Priority Review and granted Breakthrough Therapy Designation by U.S. FDA as a potential first-in-class medicine for chronic hepatitis B

Ionis presents new data from pivotal study of zilganersen in Alexander disease (AxD) at AAN 2026 Annual Meeting

Ionis to host 2026 virtual Annual Meeting of Stockholders

IONS Q1 Earnings & Sales Beat, Stock Rises on Raised '26 View

Ionis Pharmaceuticals, Inc. (IONS) Q1 2026 Earnings Call Transcript

Compared to Estimates, Ionis Pharmaceuticals (IONS) Q1 Earnings: A Look at Key Metrics

Ionis Pharmaceuticals (IONS) Reports Q1 Loss, Tops Revenue Estimates

Ionis reports first quarter 2026 financial results and highlights progress on key programs

Ionis partner GSK announces bepirovirsen accepted for Priority Review and granted Breakthrough Therapy Designation by U.S. FDA as a potential first-in-class medicine for chronic hepatitis B

Videos

Press releases

Ionis to host 2026 virtual Annual Meeting of Stockholders

Ionis reports first quarter 2026 financial results and highlights progress on key programs

Ionis partner GSK announces bepirovirsen accepted for Priority Review and granted Breakthrough Therapy Designation by U.S. FDA as a potential first-in-class medicine for chronic hepatitis B

Ionis presents new data from pivotal study of zilganersen in Alexander disease (AxD) at AAN 2026 Annual Meeting